These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 37936655)
1. Experiences of reduction and discontinuation of antipsychotics: a qualitative investigation within the RADAR trial. Morant N; Long M; Jayacodi S; Cooper R; Akther-Robertson J; Stansfeld J; Horowitz M; Priebe S; Moncrieff J EClinicalMedicine; 2023 Oct; 64():102135. PubMed ID: 37936655 [TBL] [Abstract][Full Text] [Related]
2. Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial. Moncrieff J; Crellin N; Stansfeld J; Cooper R; Marston L; Freemantle N; Lewis G; Hunter R; Johnson S; Barnes T; Morant N; Pinfold V; Smith R; Kent L; Darton K; Long M; Horowitz M; Horne R; Vickerstaff V; Jha M; Priebe S Lancet Psychiatry; 2023 Nov; 10(11):848-859. PubMed ID: 37778356 [TBL] [Abstract][Full Text] [Related]
3. Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT. Crawford MJ; Thana L; Evans R; Carne A; O'Connell L; Claringbold A; Saravanamuthu A; Case R; Munjiza J; Jayacodi S; Reilly JG; Hughes E; Hoare Z; Barrett B; Leeson VC; Paton C; Keown P; Pappa S; Green C; Barnes TR Health Technol Assess; 2020 Sep; 24(44):1-54. PubMed ID: 32930090 [TBL] [Abstract][Full Text] [Related]
4. A pilot randomised controlled trial of community-led ANtipsychotic Drug REduction for Adults with Learning Disabilities. McNamara R; Randell E; Gillespie D; Wood F; Felce D; Romeo R; Angel L; Espinasse A; Hood K; Davies A; Meek A; Addison K; Jones G; Deslandes P; Allen D; Knapp M; Thapar A; Kerr M Health Technol Assess; 2017 Aug; 21(47):1-92. PubMed ID: 28857740 [TBL] [Abstract][Full Text] [Related]
5. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A; Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925 [TBL] [Abstract][Full Text] [Related]
6. Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT. Duffy L; Clarke CS; Lewis G; Marston L; Freemantle N; Gilbody S; Hunter R; Kendrick T; Kessler D; King M; Lanham P; Mangin D; Moore M; Nazareth I; Wiles N; Bacon F; Bird M; Brabyn S; Burns A; Donkor Y; Hunt A; Pervin J; Lewis G Health Technol Assess; 2021 Nov; 25(69):1-62. PubMed ID: 34842135 [TBL] [Abstract][Full Text] [Related]
7. Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction). Moncrieff J; Lewis G; Freemantle N; Johnson S; Barnes TRE; Morant N; Pinfold V; Hunter R; Kent LJ; Smith R; Darton K; Horne R; Crellin NE; Cooper RE; Marston L; Priebe S BMJ Open; 2019 Nov; 9(11):e030912. PubMed ID: 31780589 [TBL] [Abstract][Full Text] [Related]
8. The subjective effect of antipsychotic medication on trauma-related thoughts, emotions, and physical symptoms: A qualitative study with people who have experienced childhood trauma and psychosis. Kamitsis I; Harms L; Bendall S Psychol Psychother; 2022 Mar; 95(1):256-276. PubMed ID: 34617384 [TBL] [Abstract][Full Text] [Related]
9. Mental health professionals' views and experiences of antipsychotic reduction and discontinuation. Cooper RE; Hanratty É; Morant N; Moncrieff J PLoS One; 2019; 14(6):e0218711. PubMed ID: 31220160 [TBL] [Abstract][Full Text] [Related]
10. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555 [TBL] [Abstract][Full Text] [Related]
11. Cost-Utility Analysis of Antipsychotic Reduction and Discontinuation in Patients With Long-Term Schizophrenia and Psychosis in English Mental Health Trusts: The RADAR Study. Bray G; Moncrieff J; Priebe S; Marston L; Lewis G; Haynes N; Pinfold V; Johnson S; Hunter RM Value Health; 2024 Aug; ():. PubMed ID: 39127250 [TBL] [Abstract][Full Text] [Related]
12. Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. Gumley AI; Bradstreet S; Ainsworth J; Allan S; Alvarez-Jimenez M; Birchwood M; Briggs A; Bucci S; Cotton S; Engel L; French P; Lederman R; Lewis S; Machin M; MacLennan G; McLeod H; McMeekin N; Mihalopoulos C; Morton E; Norrie J; Reilly F; Schwannauer M; Singh SP; Sundram S; Thompson A; Williams C; Yung A; Aucott L; Farhall J; Gleeson J Health Technol Assess; 2022 May; 26(27):1-174. PubMed ID: 35639493 [TBL] [Abstract][Full Text] [Related]
13. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Van Leeuwen E; Petrovic M; van Driel ML; De Sutter AI; Vander Stichele R; Declercq T; Christiaens T Cochrane Database Syst Rev; 2018 Apr; 3(3):CD007726. PubMed ID: 29605970 [TBL] [Abstract][Full Text] [Related]
14. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. Morrison AP; Law H; Carter L; Sellers R; Emsley R; Pyle M; French P; Shiers D; Yung AR; Murphy EK; Holden N; Steele A; Bowe SE; Palmier-Claus J; Brooks V; Byrne R; Davies L; Haddad PM Lancet Psychiatry; 2018 May; 5(5):411-423. PubMed ID: 29605187 [TBL] [Abstract][Full Text] [Related]
15. A qualitative exploration of family members' perspectives on reducing and discontinuing antipsychotic medication. Lewins A; Morant N; Akther-Robertson J; Crellin NE; Stansfeld JL; Smith R; Moncrieff J J Ment Health; 2024 Jun; 33(3):333-340. PubMed ID: 35521675 [TBL] [Abstract][Full Text] [Related]
16. A peer-delivered intervention to reduce harm and improve the well-being of homeless people with problem substance use: the SHARPS feasibility mixed-methods study. Parkes T; Matheson C; Carver H; Foster R; Budd J; Liddell D; Wallace J; Pauly B; Fotopoulou M; Burley A; Anderson I; MacLennan G Health Technol Assess; 2022 Feb; 26(14):1-128. PubMed ID: 35212621 [TBL] [Abstract][Full Text] [Related]
17. Experiences of taking neuroleptic medication and impacts on symptoms, sense of self and agency: a systematic review and thematic synthesis of qualitative data. Thompson J; Stansfeld JL; Cooper RE; Morant N; Crellin NE; Moncrieff J Soc Psychiatry Psychiatr Epidemiol; 2020 Feb; 55(2):151-164. PubMed ID: 31875238 [TBL] [Abstract][Full Text] [Related]
18. A contingency management intervention to reduce cannabis use and time to relapse in early psychosis: the CIRCLE RCT. Johnson S; Rains LS; Marwaha S; Strang J; Craig T; Weaver T; McCrone P; King M; Fowler D; Pilling S; Marston L; Omar RZ; Craig M; Spencer J; Hinton M Health Technol Assess; 2019 Aug; 23(45):1-108. PubMed ID: 31460865 [TBL] [Abstract][Full Text] [Related]
19. Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT. Howard R; Cort E; Bradley R; Harper E; Kelly L; Bentham P; Ritchie C; Reeves S; Fawzi W; Livingston G; Sommerlad A; Oomman S; Nazir E; Nilforooshan R; Barber R; Fox C; Macharouthu A; Ramachandra P; Pattan V; Sykes J; Curran V; Katona C; Dening T; Knapp M; Romeo R; Gray R Health Technol Assess; 2018 Nov; 22(67):1-62. PubMed ID: 30507375 [TBL] [Abstract][Full Text] [Related]